Johns Hopkins Emergency Department finds more appropriate antibiotic treatment and shorter STI visits Read more

Visby Medical


•    Press Release

Visby Medical Makes Strategic Hires to Continue Business Development

Visby Medical appoints Mark Ibison as Chief Financial Officer, Christopher J. Jowett as Chief Commercial Officer, and Alicia Zuiker as Chief People Officer
Visby new leadership hires

(From left to right): Chief Commercial Officer Christopher J. Jowett, Chief Financial Officer Mark Ibison, and Chief People Officer Alicia Zuiker.

(SAN JOSE, CA), July 16, 2021  – Today, Visby Medical, a leading medical diagnostic company, announced three strategic new hires – Mark Ibison as Chief Financial Officer, Christopher J. Jowett as Chief Commercial Officer, and Alicia Zuiker as Chief People Officer. All three will join the executive leadership team to address key areas of growth and development for the company and its signature diagnostic tests for COVID-19 and sexual health.

“In the last year, Visby Medical has seen exponential growth with our innovative PCR technology,” said Adam de la Zerda, CEO of Visby Medical. “We’re delighted to have Mark, Christopher and Alicia join the team as each of these leaders brings unique experiences and acumen that will help Visby achieve its business goals.”

Mark has over 20 years of financial management and planning across biotech and diagnostics sectors with extensive experience developing effective financial models that drive performance. Most recently, he held the position of Chief Financial Officer for Mesa Biotech, a healthcare company that utilizes rapid-PCR to provide results for infectious disease testing. Previously, he was the Chief Financial Officer for SOLVD Health and Vice President of Finance for Thermo Fisher Biosciences. Mark is currently an associate member of the Chartered Institute of Management Accountants and the Association of Corporate Treasurers.

Christopher joins Visby with in-depth knowledge of the diagnostics sector and over 30 years of sales, marketing, and operational leadership experience. He was previously Vice President of Molecular Diagnostic Sales, North America, at QIAGEN Inc., a provider of sample and assay technologies of molecular diagnostics, and has held various leadership roles within Abbott Laboratories. Christopher has proven success in driving business outcomes in the diagnostics industry and will be essential to Visby’s growth as they continue to deliver new products and innovations.

Alicia will step into her role bringing over 16 years of experience in human resources – spanning organizational design and transformation, culture and talent management, executive coaching, and Diversity, Equity & Inclusion (DE&I) expertise. Most recently, she held the position of Director People Operations, Customer Experience at Google, and prior to that, she was VP of Human Resources at GE. Alicia will be crucial in helping build and define our culture, growing teams, and fostering individual growth to meet our collective business objectives.

About Visby Medical™

Visby Medical has been working to change the order of diagnosis and treatment of infectious disease for a decade. Visby Medical has a single-use PCR test to rapidly test for serious infections. Tested, reviewed, and endorsed by top public and private organizations, the first commercial application of the Visby Medical technology received FDA Emergency Use Authorization in 2020 for moderate-complexity laboratory testing of symptomatic patients in the fight against COVID-19, and in 2021 for use in settings with a CLIA Certificate of Waiver. Visby is gaining government and private partnerships to accelerate the delivery of PCR-grade diagnostics, designed for use at the point of care, and eventually for use at home.

For more information, visit Follow Visby Medical on LinkedIn at; Facebook, Instagram, and Twitter @VisbyMedical.

Contact: (240) 839-0945 |

Read more articles & insights

Visby Medical™ Sexual Health Test Results in More Appropriate Antibiotic Treatment and Shorter Emergency Department Visits Than Standard of Care

Point-of-Care test significantly shortens time from ED arrival to test results, treatment and discharge – significant improvements are seen in the use of antibiotics for the treatment of chlamydia and gonococcal infections in women. Nationwide increases in sexually transmitted diseases and antibiotic resistance create the need for a paradigm shift from traditional lab-based molecular testing.

Read More